PRLD
Prelude Therapeutics IncorporatedNASDAQHealthcare$3.46+0.29%ClosedMarket Cap: $192.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.38
P/S
16.89
EV/EBITDA
-1.84
DCF Value
$5.10
FCF Yield
-27.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
93.1%
Operating Margin
-861.3%
Net Margin
-819.6%
ROE
-130.0%
ROA
-70.4%
ROIC
-114.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $5.6M | 92.6% | $-17.3M | $-16.5M | $-0.26 | — |
| FY 2025 | $12.1M | 85.9% | $-104.6M | $-99.5M | $-1.29 | — |
| Q3 2025 | $6.5M | 93.5% | $-20.4M | $-19.7M | $-0.26 | — |
| Q2 2025 | $0.00 | NaN% | $-32.2M | $-31.2M | $-0.41 | — |
| Q1 2025 | $0.00 | NaN% | $-34.6M | $-32.1M | $-0.42 | — |
| Q4 2024 | $4.0M | 100.0% | $-33.8M | $-28.7M | $-0.38 | — |
| FY 2024 | $7.0M | 100.0% | $-139.7M | $-127.2M | $-1.68 | — |
| Q3 2024 | $3.0M | 100.0% | $-34.4M | $-32.3M | $-0.43 | — |
| Q2 2024 | $0.00 | NaN% | $-37.2M | $-34.7M | $-0.46 | — |
| Q1 2024 | $0.00 | NaN% | $-34.3M | $-31.4M | $-0.42 | — |
| Q4 2023 | $0.00 | -Infinity% | $-37.4M | $-33.1M | $-0.48 | — |
| FY 2023 | $0.00 | NaN% | $-132.3M | $-121.8M | $-2.02 | — |